One-hundred days monitoring patients submitted to hematopoietic stem cell transplantation: Events of metabolic syndrome
DOI:
https://doi.org/10.24220/2318-0897v23n1a2412Keywords:
Body composition, Hematopoietic stem cell transplantation, Lipids, Metabolic syndromeAbstract
Objective
This study assessed early manifestations of metabolic syndrome determinants in patients submitted to hematopoietic stem cell transplantation.
Methods
Twenty-seven individuals participated in the study (20 with autologous and 7 with allogeneic hematopoietic stem cell transplantation). Anthropometric variables and biochemical indicators of lipid and glucose metabolism were determined before and 100 days after hematopoietic stem cell transplantation.
Results
The mean total cholesterol (p=0.086), very low density lipoprotein-cholesterol (p=0.069) and triglycerides (p=0.086) of all patients did not change significantly between the two study periods, but when the patients were separated by type of hematopoietic stem cell transplantation, triglycerides and very low density lipoprotein-cholesterol were close to the critical level of significance for individuals with allogeneic hematopoietic stem cell transplantation (p=0.060) and total cholesterol was significant in individuals
with autologous hematopoietic stem cell transplantation (p=0.027). Anthropometric variables did not change significantly between before and 100 days after hematopoietic stem cell transplantation.
Conclusion
Metabolic syndrome risk factors may be associated with lipid metabolism in the early phase of allogeneic and autologous hematopoietic stem cell transplantation.
Downloads
References
Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL. Metabolic syndrome in patients with hematological diseases. Expert Rev Hematol. 2012; 5(4):439-58.
Annaloro C, Onida F, Saporiti G, Lambertenghi Deliliers G. Cancer stem cells in hematological disorders: Current and possible new therapeutic approaches. Curr Pharm Biotechnol. 2011; 12(2):217-25.
Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(9):797-804.
Federation ID. The IDF consensus worldwide definition of the metabolic syndrome. Belgium: International Diabetes Federation; 2006.
Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: The Norwegian HUNT 2 study. BMC Public Health. 2007; 7:220.
Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gonzalez-Sanchez JL, Seclen S, Villena A, et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care. 2006; 29(3):685-91.
Mannucci E, Monami M, Cresci B, Pala L, Bardini G, Petracca MG, et al. National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno a Ripoli study. Diabetes Obesity Metabol. 2008; 10(5):430-5.
Mertens I, Van Gaal LF. New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thrombosis Haemostasis. 2006; 4(5):1164-6.
Nawabzad R, Champin B. [Concordance between three definitions for metabolic syndrome (Hypertriglyceridemic waist, National Cholesterol Education Program, International Diabetes Federation), and prevalence of the syndrome in a French population]. Rev Prat. 2010; 60(10 Suppl):15-23.
Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease? Intern J Preventive Medicine. 2012; 3(8):552-8.
Rodriguez A, Delgado-Cohen H, Reviriego J, Serrano-Rios M. Risk factors associated with metabolic syndrome in type 2 diabetes Mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions. Diabetes Metab Syndr Obes. 2011; 4:1-4.
Yoon YS, Lee ES, Park C, Lee S, Oh SW. The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: The Korea NHANES study. Inter J Obesity. 2007; 31(3):528-34.
Martin-Salces M, de Paz R, Canales MA, Mesejo A, Hernandez-Navarro F. Nutritional recommendations in hematopoietic stem cell transplantation. Nutrition. 2008; 24(7-8):769-75.
Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplan. 2009; 43(1):49-54.
Baker KS, Armenian S, Bhatia S. Long-term consequences of hematopoietic stem cell transplantation: Current state of the science. Biol Blood Marrow Transplant. 2010; 16(1 Suppl):S90-6.
Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(5):619-25.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143-238.
Nagao K, Yanagita T. Bioactive lipids in metabolic syndrome. Progress Lipid Res. 2008; 47(2):127-46.
